HANSOH PHARMA GRANTS GLENMARK EXCLUSIVE MULTI-REGIONAL RIGHTS REGARDING AUMOLERTINIB

ESMO ASIA | HANSOH PHARMA ANNOUNCES RESULTS OF RESENCATINIB (HS-10365，A HIGHLY SELECTIVE RET INHIBITOR）FOR THE TREATMENT OF PATIENTS WITH RET-FUSION LOCALLY ADVANCED OR METASTATIC NSCLC

HANSOH PHARMA: TWO NEW INDICATIONS OF ALMONERTINIB ADDED TO THE 2025 NRDL; MULTIPLE INNOVATIVE DRUGS RENEWED

HANSOH PHARMA ANNOUNCES ORAL PRESENTATION OF PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4 ADC) IN PLATINUM-RESISTANT OVARIAN CANCER AT IGCS 2025

ESMO 2025 | HANSOH PHARMA ANNOUNCES PROFFERED PAPER PRESENTATION OF PHASE 2 STUDY ON HS-20093 (B7-H3-TARGETED ADC) IN RELAPSED OR REFRACTORY SARCOMAS

ESMO 2025 | HANSOH PHARMA PRESENTS THE PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4-TARGETED ADC), IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC)

DRUG REGISTRATION APPROVAL OF THE SECOND INDICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

HANSOH PHARMA | AUMOLERTINIB: APPROVED BY UK’S MHRA FOR THE TREATMENT OF NSCLC — MARKING THE FIRST OVERSEAS LAUNCH OF CHINA-DEVELOPED EGFR-TKI